In the monarchE trial, CDK4/6 inhibitor plus standard endocrine therapy has shown statistically significant improvement in invasive disease-free survival (IDFS) compared with endocrine therapy alone for HR-positive, HER2-negative, node-positive early breast cancer (EBC) with a high risk of recurrence. Here, ERBB2 is linked to breast carcinoma.